{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T07:37:53Z","timestamp":1786865873209,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T00:00:00Z","timestamp":1730505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Taiwan University Cancer Center","award":["NTUCCS-112-15 and NTUCCS-113-27"],"award-info":[{"award-number":["NTUCCS-112-15 and NTUCCS-113-27"]}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MST 110-2314-B-002-138-MY3"],"award-info":[{"award-number":["MST 110-2314-B-002-138-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We investigated the combined effects of ataxia telangiectasia and Rad3-related (ATR) inhibition, ablative radiotherapy, and immune checkpoint inhibitor (ICI) therapy against lung cancer. ATR inhibitor was administered combined with ablative radiotherapy to assess its radiosensitizing effect on lung cancer cells. Treatment response and survival were evaluated in vivo using A549 xenograft flank tumor and synchronous LLC lung and flank tumor mouse models. Mice received ablative radiotherapy (12\u00a0Gy\/d for 2 d), ATR inhibitor, and ICI. The tumor microenvironment was assessed in irradiated flank and non-irradiated lung tumors. Programmed death-ligand 1 expression was upregulated after irradiation. ATR inhibition attenuated this upregulation. ATR inhibitor pretreatment decreased cell survival after irradiation by inhibiting DNA double-strand break repair, inducing mitotic cell death, and altering cell cycle progression. ATR inhibition enhanced radiation-induced damage-associated molecular patterns determined by high mobility group box 1 quantification and activated the cyclic GMP-AMP synthase-stimulator of interferon genes pathway. Combined ATR inhibition and ablative radiotherapy inhibited tumor growth and improved survival in mice. Adding ICI therapy further enhanced local antitumor effects, reducing the metastatic lung tumor burden and remodeling the tumor microenvironment through immunogenic cell death induction and enhanced immune cell infiltration. Triple therapy increased immune cell infiltration in distant non-irradiated lung tumors and stimulated the generation of protective T-cell immunity in splenocytes. Safety analysis showed minimal toxicity. ATR inhibition enhanced the efficacy of ablative radiotherapy and immunotherapy in lung cancer. These findings underscore the importance of combination therapies for enhancing systemic antitumor immune responses and outcomes.<\/jats:p>","DOI":"10.1007\/s00262-024-03864-6","type":"journal-article","created":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T09:03:07Z","timestamp":1730538187000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combination of ataxia telangiectasia and Rad3-related inhibition with ablative radiotherapy remodels the tumor microenvironment and enhances immunotherapy response in lung cancer"],"prefix":"10.1007","volume":"74","author":[{"given":"Jenny Ling-Yu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Kai","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Cheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Sen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Hsuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Jyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Hsin","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Li","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,2]]},"reference":[{"key":"3864_CR1","first-page":"327","volume":"4","author":"F Islami","year":"2015","unstructured":"Islami F, Torre LA, Jemal A (2015) Global trends of lung cancer mortality and smoking prevalence. Transl Lung Cancer Res 4:327\u2013338","journal-title":"Transl Lung Cancer Res"},{"key":"3864_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s00066-018-1418-8","volume":"195","author":"YS Huang","year":"2019","unstructured":"Huang YS, Chen JL, Chen JY, Lee YF, Huang JY, Kuo SH, Yen RF, Chang YC (2019) Predicting tumor responses and patient survival in chemoradiotherapy-treated patients with non-small-cell lung cancer using dynamic contrast-enhanced integrated magnetic resonance-positron-emission tomography. Strahlenther Onkol 195:707\u2013718","journal-title":"Strahlenther Onkol"},{"key":"3864_CR3","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Fr\u00fch M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O (2019) Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 30:1321\u20131328","journal-title":"Ann Oncol"},{"key":"3864_CR4","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00262-020-02690-w","volume":"70","author":"JL Chen","year":"2021","unstructured":"Chen JL, Pan CK, Huang YS, Tsai CY, Wang CW, Lin YL, Kuo SH, Shieh MJ (2021) Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors. Cancer Immunol Immunother 70:391\u2013404","journal-title":"Cancer Immunol Immunother"},{"key":"3864_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1146\/annurev-med-042320-025136","volume":"73","author":"NYL Ngoi","year":"2022","unstructured":"Ngoi NYL, Peng G, Yap TA (2022) A Tale of two checkpoints: ATR inhibition and PD-(L)1 blockade. Annu Rev Med 73:231\u2013250","journal-title":"Annu Rev Med"},{"key":"3864_CR6","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/jmri.25758","volume":"47","author":"YS Huang","year":"2018","unstructured":"Huang YS, Chen JL, Hsu FM, Huang JY, Ko WC, Chen YC, Jaw FS, Yen RF, Chang YC (2018) Response assessment of stereotactic body radiation therapy using dynamic contrast-enhanced integrated MR-PET in non-small cell lung cancer patients. J Magn Reson Imaging 47:191\u2013199","journal-title":"J Magn Reson Imaging"},{"key":"3864_CR7","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1038\/onc.2016.104","volume":"35","author":"C Hernandez","year":"2016","unstructured":"Hernandez C, Huebener P, Schwabe RF (2016) Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene 35:5931\u20135941","journal-title":"Oncogene"},{"key":"3864_CR8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ijrobp.2023.02.014","volume":"116","author":"JL Chen","year":"2023","unstructured":"Chen JL, Yang SJ, Pan CK, Lin LC, Tsai CY, Wang CH, Huang YS, Lin YL, Kuo SH, Shieh MJ (2023) Cisplatin and albumin-based gold-cisplatin nanoparticles enhance ablative radiation therapy-induced antitumor immunity in local and distant tumor microenvironment. Int J Radiat Oncol Biol Phys 116:1135\u20131149","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3864_CR9","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1140321","volume":"316","author":"S Matsuoka","year":"2007","unstructured":"Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316:1160\u20131166","journal-title":"Science"},{"key":"3864_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.114126","volume":"158","author":"S Sriramulu","year":"2023","unstructured":"Sriramulu S, Thoidingjam S, Brown SL, Siddiqui F, Movsas B, Nyati S (2023) Molecular targets that sensitize cancer to radiation killing: from the bench to the bedside. Biomed Pharmacother 158:114126","journal-title":"Biomed Pharmacother"},{"key":"3864_CR11","doi-asserted-by":"publisher","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","volume":"27","author":"Z Tang","year":"2021","unstructured":"Tang Z, Pili\u00e9 PG, Geng C, Manyam GC, Yang G, Park S, Wang D, Peng S, Wu C, Peng G, Yap TA, Corn PG, Broom BM, Thompson TC (2021) ATR inhibition induces CDK1-SPOP signaling and enhances Anti-PD-L1 cytotoxicity in prostate cancer. Clin Cancer Res 27:4898\u20134909","journal-title":"Clin Cancer Res"},{"key":"3864_CR12","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1158\/1078-0432.CCR-18-1821","volume":"25","author":"MT Dillon","year":"2019","unstructured":"Dillon MT, Bergerhoff KF, Pedersen M, Whittock H, Crespo-Rodriguez E, Patin EC, Pearson A, Smith HG, Paget JTE, Patel RR, Foo S, Bozhanova G, Ragulan C, Fontana E, Desai K, Wilkins AC, Sadanandam A, Melcher A, McLaughlin M, Harrington KJ (2019) ATR inhibition potentiates the radiation-induced inflammatory tumor microenvironment. Clin Cancer Res 25:3392\u20133403","journal-title":"Clin Cancer Res"},{"key":"3864_CR13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cac2.12412","volume":"43","author":"C Liu","year":"2023","unstructured":"Liu C, Wang X, Qin W, Tu J, Li C, Zhao W, Ma L, Liu B, Qiu H, Yuan X (2023) Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer. Cancer Commun (Lond) 43:435\u2013454","journal-title":"Cancer Commun (Lond)"},{"key":"3864_CR14","first-page":"1307","volume":"8","author":"LL Sun","year":"2018","unstructured":"Sun LL, Yang RY, Li CW, Chen MK, Shao B, Hsu JM, Chan LC, Yang Y, Hsu JL, Lai YJ, Hung MC (2018) Inhibition of ATR downregulates PD-L1 and sensitizes tumor cells to T cell-mediated killing. Am J Cancer Res 8:1307\u20131316","journal-title":"Am J Cancer Res"},{"key":"3864_CR15","doi-asserted-by":"publisher","first-page":"3926","DOI":"10.1172\/JCI96519","volume":"128","author":"FP Vendetti","year":"2018","unstructured":"Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O\u2019Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ (2018) ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. J Clin Invest 128:3926\u20133940","journal-title":"J Clin Invest"},{"key":"3864_CR16","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1158\/1535-7163.MCT-21-0305","volume":"20","author":"AM Baschnagel","year":"2021","unstructured":"Baschnagel AM, Elnaggar JH, VanBeek HJ, Kromke AC, Skiba JH, Kaushik S, Abel L, Clark PA, Longhurst CA, Nickel KP, Leal TA, Zhao SG, Kimple RJ (2021) ATR Inhibitor M6620 (VX-970) Enhances the effect of radiation in non-small cell lung cancer brain metastasis patient-derived xenografts. Mol Cancer Ther 20:2129\u20132139","journal-title":"Mol Cancer Ther"},{"key":"3864_CR17","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1158\/1535-7163.MCT-18-0470","volume":"17","author":"X Tu","year":"2018","unstructured":"Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, Harmsen WS, Yuan J, Boughey JC, Goetz MP, Sarkaria JN, Lou Z, Mutter RW (2018) ATR inhibition is a promising radiosensitizing strategy for triple-negative breast cancer. Mol Cancer Ther 17:2462\u20132472","journal-title":"Mol Cancer Ther"},{"key":"3864_CR18","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.radonc.2016.10.023","volume":"121","author":"KB Leszczynska","year":"2016","unstructured":"Leszczynska KB, Dobrynin G, Leslie RE, Ient J, Boumelha AJ, Senra JM, Hawkins MA, Maughan T, Mukherjee S, Hammond EM (2016) Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer. Radiother Oncol 121:232\u2013238","journal-title":"Radiother Oncol"},{"key":"3864_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/978-1-4939-6346-1_9","volume":"1473","author":"SA Shahane","year":"2016","unstructured":"Shahane SA, Nishihara K, Xia M (2016) High-Throughput and high-content micronucleus assay in CHO-K1 cells. Methods Mol Biol 1473:77\u201385","journal-title":"Methods Mol Biol"},{"key":"3864_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1124\/jpet.121.000845","volume":"379","author":"S Talele","year":"2021","unstructured":"Talele S, Zhang W, Burgenske DM, Kim M, Mohammad AS, Dragojevic S, Gupta SK, Bindra RS, Sarkaria JN, Elmquist WF (2021) Brain distribution of berzosertib: an ataxia telangiectasia and rad3-related protein inhibitor for the treatment of glioblastoma. J Pharmacol Exp Ther 379:343\u2013357","journal-title":"J Pharmacol Exp Ther"},{"key":"3864_CR21","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, Benci JL, Xu B, Dada H, Odorizzi PM, Herati RS, Mansfield KD, Patsch D, Amaravadi RK, Schuchter LM, Ishwaran H, Mick R, Pryma DA, Xu X, Feldman MD, Gangadhar TC, Hahn SM, Wherry EJ, Vonderheide RH, Minn AJ (2015) Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:373\u2013377","journal-title":"Nature"},{"key":"3864_CR22","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman AD, Fritz JM, Lenardo MJ (2020) A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol 20:651\u2013668","journal-title":"Nat Rev Immunol"},{"key":"3864_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000340","volume":"8","author":"H Sheng","year":"2020","unstructured":"Sheng H, Huang Y, Xiao Y, Zhu Z, Shen M, Zhou P, Guo Z, Wang J, Wang H, Dai W, Zhang W, Sun J, Cao C (2020) ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma. J Immunother Cancer 8:e000340","journal-title":"J Immunother Cancer"},{"key":"3864_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00066-021-01835-9","volume":"197","author":"JL Chen","year":"2021","unstructured":"Chen JL, Pan CK, Lin YL, Tsai CY, Huang YS, Yang WC, Hsu FM, Kuo SH, Shieh MJ (2021) Preclinical evaluation of PEGylated liposomal doxorubicin as an effective radiosensitizer in chemoradiotherapy for lung cancer. Strahlenther Onkol 197:1131\u20131142","journal-title":"Strahlenther Onkol"},{"key":"3864_CR25","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1097\/HP.0000000000000462","volume":"110","author":"NP Brodin","year":"2016","unstructured":"Brodin NP, Chen Y, Yaparpalvi R, Guha C, Tom\u00e9 WA (2016) Dosimetry formalism and implementation of a homogenous irradiation protocol to improve the accuracy of small animal whole-body irradiation using a 137cs irradiator. Health Phys 110:S26-38","journal-title":"Health Phys"},{"key":"3864_CR26","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.ijrobp.2022.07.034","volume":"115","author":"YS Huang","year":"2023","unstructured":"Huang YS, Chen JL, Lan HT, Tai MH, Kuo SH, Shih JY, Chang YC (2023) Xenon-enhanced ventilation computed tomography for functional lung avoidance radiation therapy in patients with lung cancer. Int J Radiat Oncol Biol Phys 115:356\u2013365","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3864_CR27","doi-asserted-by":"publisher","first-page":"3727","DOI":"10.1158\/1078-0432.CCR-14-2824","volume":"21","author":"A Filatenkov","year":"2015","unstructured":"Filatenkov A, Baker J, Mueller AM, Kenkel J, Ahn GO, Dutt S, Zhang N, Kohrt H, Jensen K, Dejbakhsh-Jones S, Shizuru JA, Negrin RN, Engleman EG, Strober S (2015) Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions. Clin Cancer Res 21:3727\u20133739","journal-title":"Clin Cancer Res"},{"key":"3864_CR28","first-page":"366","volume":"17","author":"J Luo","year":"2018","unstructured":"Luo J, Pi G, Xiao H, Ye Y, Li Q, Zhao L, Huang H, Luo H, Zhang Q, Wang D, Wang G (2018) Torin2 enhances the radiosensitivity of MCF-7 breast cancer cells by downregulating the mTOR signaling pathway and ATM phosphorylation. Mol Med Rep 17:366\u2013373","journal-title":"Mol Med Rep"},{"key":"3864_CR29","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s10147-020-01666-1","volume":"25","author":"H Sato","year":"2020","unstructured":"Sato H, Okonogi N, Nakano T (2020) Rationale of combination of anti-PD-1\/PD-L1 antibody therapy and radiotherapy for cancer treatment. Int J Clin Oncol 25:801\u2013809","journal-title":"Int J Clin Oncol"},{"key":"3864_CR30","doi-asserted-by":"publisher","first-page":"1201500","DOI":"10.3389\/fonc.2023.1201500","volume":"13","author":"H Paganetti","year":"2023","unstructured":"Paganetti H (2023) A review on lymphocyte radiosensitivity and its impact on radiotherapy. Front Oncol 13:1201500","journal-title":"Front Oncol"},{"key":"3864_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12943-020-01250-1","volume":"19","author":"J Zheng","year":"2020","unstructured":"Zheng J, Mo J, Zhu T, Zhuo W, Yi Y, Hu S, Yin J, Zhang W, Zhou H, Liu Z (2020) Comprehensive elaboration of the cGAS-STING signaling axis in cancer development and immunotherapy. Mol Cancer 19:133","journal-title":"Mol Cancer"},{"key":"3864_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-023-00609-z","volume":"10","author":"M Chen","year":"2024","unstructured":"Chen M, Yu S, van der Sluis T, Zwager MC, Schr\u00f6der CP, van der Vegt B, van Vugt MATM (2024) cGAS-STING pathway expression correlates with genomic instability and immune cell infiltration in breast cancer. NPJ Breast Cancer 10:1","journal-title":"NPJ Breast Cancer"},{"key":"3864_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.21037\/tlcr-20-524","volume":"10","author":"GK Raaby","year":"2020","unstructured":"Raaby GK, Sandfeld PB, Godsk SH, Demuth C, Meldgaard P, Sorensen BS, Jakobsen MR (2020) cGAS-STING pathway expression as a prognostic tool in NSCLC. Transl Lung Cancer Res 10:340\u2013354","journal-title":"Transl Lung Cancer Res"},{"key":"3864_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004306","volume":"10","author":"EC Patin","year":"2022","unstructured":"Patin EC, Dillon MT, Nenclares P, Grove L, Soliman H, Leslie I, Northcote D, Bozhanova G, Crespo-Rodriguez E, Baldock H, Whittock H, Baker G, Kyula J, Guevara J, Melcher AA, Harper J, Ghadially H, Smith S, Pedersen M, McLaughlin M, Harrington KJ (2022) Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade. J Immunother Cancer 10:e004306","journal-title":"J Immunother Cancer"},{"key":"3864_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001845","volume":"9","author":"JG Zhou","year":"2021","unstructured":"Zhou JG, Donaubauer AJ, Frey B, Becker I, Rutzner S, Eckstein M, Sun R, Ma H, Schubert P, Schweizer C, Fietkau R, Deutsch E, Gaipl U, Hecht M (2021) Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent\/metastatic cancer to immune checkpoint inhibitors. J Immunother Cancer 9:e001845","journal-title":"J Immunother Cancer"},{"key":"3864_CR36","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.radonc.2017.06.025","volume":"124","author":"V Dunne","year":"2017","unstructured":"Dunne V, Ghita M, Small DM, Coffey CBM, Weldon S, Taggart CC, Osman SO, McGarry CK, Prise KM, Hanna GG, Butterworth KT (2017) Inhibition of ataxia telangiectasia related-3 (ATR) improves therapeutic index in preclinical models of non-small cell lung cancer (NSCLC) radiotherapy. Radiother Oncol 124:475\u2013481","journal-title":"Radiother Oncol"},{"key":"3864_CR37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41416-023-02542-1","volume":"130","author":"SR Javed","year":"2024","unstructured":"Javed SR, Lord S, El Badri S, Harman R, Holmes J, Kamzi F, Maughan T, McIntosh D, Mukherjee S, Ooms A, Radhakrishna G, Shaw P, Hawkins MA (2024) CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method. Br J Cancer 130:467\u2013475","journal-title":"Br J Cancer"},{"key":"3864_CR38","doi-asserted-by":"publisher","first-page":"3195","DOI":"10.1200\/JCO.19.02404","volume":"38","author":"TA Yap","year":"2020","unstructured":"Yap TA, O\u2019Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS (2020) Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors. J Clin Oncol 38:3195\u20133204","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03864-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03864-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03864-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T17:49:25Z","timestamp":1738259365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03864-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,2]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3864"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03864-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,2]]},"assertion":[{"value":"28 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"8"}}